Al-Mekaini, Lolowa A. Kamal, Salwa M. Al-Jabri, Omer Soliman, Maher Alshamsi, Huda Narchi, Hassib Souid, Abdul-Kader and Alsuwaidi, Ahmed R. 2016. Seroprevalence of vaccine-preventable diseases among young children in the United Arab Emirates. International Journal of Infectious Diseases, Vol. 50, p. 67.
Kenny, Lena O'Kelly, Edwin Connell, Jeff De Gascun, Cillian and Hassan, Jaythoon 2016. Mumps outbreaks in a highly vaccinated population: Investigation of a neutralization titre against the current circulating wildtype genotype G5 mumps virus. Journal of Clinical Virology, Vol. 74, p. 8.
Vygen, Sabine Fischer, Aurélie Meurice, Laure Mounchetrou Njoya, Ibrahim Gregoris, Marina Ndiaye, Bakhao Ghenassia, Adrien Poujol, Isabelle Stahl, Jean Paul Antona, Denise Le Strat, Yann Levy-Bruhl, Daniel and Rolland, Patrick 2016. Waning immunity against mumps in vaccinated young adults, France 2013. Eurosurveillance, Vol. 21, Issue. 10,
Barrabeig, Irene Costa, Josep Rovira, Ariadna Marcos, M Angeles Isanta, Ricard López-Adalid, Rubén Cervilla, Ana Torner, Nuria and Domínguez, Angela 2015. Viral etiology of mumps-like illnesses in suspected mumps cases reported in Catalonia, Spain. Human Vaccines & Immunotherapeutics, Vol. 11, Issue. 1, p. 282.
Leuridan, E. Maertens, K. Wautier, M. Hutse, V. and Theeten, H. 2015. Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium. European Journal of Pediatrics, Vol. 174, Issue. 7, p. 925.
Maple, Peter 2015. Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs. Vaccines, Vol. 3, Issue. 4, p. 988.
Santacruz-Sanmartín, Eduardo Hincapié-Palacio, Doracelly Ospina, Marta C. Perez-Toro, Olga Bernal-Restrepo, Luz M. Buitrago-Giraldo, Seti Lenis-Ballesteros, Viviana and Díaz, Francisco J. 2015. Seroprevalence of mumps in an epidemic period in Medellín, Colombia. Vaccine, Vol. 33, Issue. 42, p. 5606.
Zamir, C Stein Schroeder, H Shoob, H Abramson, N and Zentner, G 2015. Characteristics of a large mumps outbreak: Clinical severity, complications and association with vaccination status of mumps outbreak cases. Human Vaccines & Immunotherapeutics, Vol. 11, Issue. 6, p. 1413.
Abrams, S. Beutels, P. and Hens, N. 2014. Assessing Mumps Outbreak Risk in Highly Vaccinated Populations Using Spatial Seroprevalence Data. American Journal of Epidemiology, Vol. 179, Issue. 8, p. 1006.
Bouricha, Mehdi Samad, Marc Abdul Levy, Pierre‐Yves Raoult, Didier and Drancourt, Michel 2014. Point‐of‐Care Syndrome‐Based, Rapid Diagnosis of Infections on Commercial Ships. Journal of Travel Medicine, Vol. 21, Issue. 1, p. 12.
Hukic, M Hajdarpasic, A Ravlija, J Ler, Z Baljic, R Dedeic Ljubovic, A Moro, A Salimović-Besic, I Sausy, A Muller, C and Hübschen, J 2014. Mumps outbreak in the Federation of Bosnia and Herzegovina with large cohorts of susceptibles and genetically diverse strains of genotype G, Bosnia and Herzegovina, December 2010 to September 2012. Eurosurveillance, Vol. 19, Issue. 33, p. 20879.
Kelly, Tara A. O’Lorcain, Piaras Moran, Joanne Garvey, Patricia McKeown, Paul Connell, Jeff and Cotter, Suzanne 2013. Underreporting of Viral Encephalitis and Viral Meningitis, Ireland, 2005–2008. Emerging Infectious Diseases, Vol. 19, Issue. 9, p. 1428.
Takla, A Wichmann, O Hautmann, W and Rieck, T 2013. Mumps epidemiology in Germany 2007-11. Eurosurveillance, Vol. 18, Issue. 33, p. 20557.
Coffinières, E. Turbelin, C. Riblier, D. Aouba, A. Levy-Bruhl, D. Arena, C. Chiappe, S. Gonzalez Ferry, J.P. Hanslik, T. and Blanchon, T. 2012. Mumps: Burden of disease in France. Vaccine, Vol. 30, Issue. 49, p. 7013.
Mumps outbreaks have recently been recorded in a number of highly vaccinated populations. We related seroprevalence, epidemiological and vaccination data from 18 European countries participating in The European Sero-Epidemiology Network (ESEN) to their risk of mumps outbreaks in order to inform vaccination strategies. Samples from national population serum banks were collected, tested for mumps IgG antibodies and standardized for international comparisons. A comparative analysis between countries was undertaken using age-specific mumps seroprevalence data and information on reported mumps incidence, vaccine strains, vaccination programmes and vaccine coverage 5–12 years after sera collection. Mean geometric mumps antibody titres were lower in mumps outbreak countries [odds ratio (OR) 0·09, 95% confidence interval (CI) 0·01–0·71)]. MMR1 vaccine coverage ⩾95% remained protective in a multivariable model (P < 0·001), as did an interval of 4–8 years between doses (OR 0·08, 95% CI 0·01–0·85). Preventing outbreaks and controlling mumps probably requires several elements, including high-coverage vaccination programmes with MMR vaccine with 4–8 years between doses.
This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.